1.
Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium
2.
3.
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.
4.
5.
6.
7.
8.
9.
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study